Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
figureposted on 2020-11-16, 09:33 authored by Edward E. Neuberger, Ibrahim M. Abbass, Eddie Jones, Natalie J. Engmann
Article full text
The above summary slide and plain language summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.